Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
2025 · 3rd Quarter (July 1 - Sep 30)
GILEAD SCIENCES INC.
Filed by FARRAGUT PARTNERS LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- FARRAGUT PARTNERS LLP
- Client
- GILEAD SCIENCES INC.
- Filing UUID
- b04e5ba0-3703-4669-bedd-a6fba2f2d2a6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues pertaining to the 340B drug discount program.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.